Weekly Watchlist: ARKG, PTC Inc. & 3 Member Analyses

August 2, 2026

PTC Inc. (PTC)

It was a difficult choice between PTC and Autodesk, as both companies offer exposure to the growing demand for engineering software, industrial automation, and AI assisted design. Autodesk is arguably the stronger company on paper, with faster growth and a larger ecosystem. However, PTC stood out as the more interesting stock at its current valuation (after the sell-off), and the more direct play on automated manufacturing, digital twins, software defined products, and physical AI.

PTC and Nvidia

The decision became easier after looking at PTC’s expanding relationship with Nvidia. The two companies are connecting PTC’s engineering software with Nvidia’s simulation and physical AI ecosystem, giving manufacturers a way to move product designs into realistic virtual environments before committing the time and money required to build them in the real world.

PTC is integrating Nvidia Omniverse technology with Creo and Windchill, its two most important engineering platforms. Creo is used to design physical products, while Windchill stores and manages the data behind those designs. Bringing that information into Omniverse allows engineers to create “digital twins”, run simulations, collaborate on designs, and identify potential problems before a physical prototype reaches production. PTC is also connecting its cloud based Onshape design platform directly with Nvidia Isaac Sim, which is used to simulate and test robots in physically accurate virtual environments.

This does not mean PTC will suddenly generate Nvidia like growth, and investors should avoid treating every Nvidia partnership as an automatic financial catalyst. The relationship is still more important strategically than financially. It strengthens the case that PTC’s software could become an important bridge between traditional engineering and the emerging world of robotics, digital twins, and physical AI.

Latest Financial Update

PTC's latest earnings reinforced the idea that this remains a steady execution story rather than a hyper growth software company. The company continues to generate strong ARR growth, strong recurring cash flow, and healthy margins while aggressively doing buybacks. Management also remains focused on its Intelligent Product Lifecycle strategy, believing AI will increase the value of the engineering data already stored across its software portfolio.

The biggest risk remains growth. While the business is performing well operationally, investors will likely want to see AI products translate into faster revenue acceleration over the next several years. Until then, the investment case relies on steady execution, recurring revenue growth, expanding cash flow, and continued capital returns.

ARK Genomic Revolution ETF (ARKG)

Price target: Members Only

The ARK Genomic Revolution Fund is no stranger to us at Hyper Stocks…this is a name we’ve covered for years in anticipation of rapid development in precision medicine and gene editing. In our initial analysis, published in December 2024, we pointed out that the global genome editing market reached a valuation of $7.38 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 17.18%, reaching an impressive $30 billion by 2032. Since then, the industry has continued moving in the direction we expected. The biggest difference today is that gene editing is not just being tested in laboratories, it is beginning to produce approved treatments and commercial revenue, something that is standing out to investors already.

Since our analysis in late 2024, ARKG has doubled in value, returning 100% to those who held. Much of the gain came in the past three months, perhaps because of CRISPR Therapeutics’ (one of ARKG’s biggest holdings) major win with Vertex Pharmaceuticals. Note that we’re holding $CRSP already as part of the Hyper Stocks swings…we’ll continue managing it and consider scaling into more of the industry as long as $ARKG holds the trend.

CRISPR Therapeutics Delivers a Major Win

CRISPR Therapeutics and Vertex Pharmaceuticals originally made history with CASGEVY, the world’s first approved treatment built using CRISPR/Cas9 gene editing technology. The treatment is designed for patients with sickle cell disease and transfusion dependent beta thalassemia, two serious inherited blood disorders.

The latest win came on July 1, 2026, when the FDA expanded CASGEVY’s approval to include patients as young as two years old. It had previously been limited to patients ages 12 and older. This is a major development because genetic diseases can cause permanent organ damage over time. Treating children earlier may allow doctors to intervene before years of complications begin piling up. The expanded approval also dramatically increases the number of patients who could potentially qualify for the treatment. The significance goes beyond one product. CASGEVY has proven that CRISPR technology can make the jump from theory to an FDA approved medicine capable of treating the underlying cause of a genetic disease.

Commercialization Is Beginning to Take Shape

The next test for the industry is whether these groundbreaking treatments can become scalable businesses. CASGEVY is not generating billions, nor will it for a long time (if ever). However, it serves as validation for the company’s broader gene editing platform. If CASGEVY represents the first generation of gene editing, the next generation could involve treatments that are easier to manufacture, easier to administer, and capable of addressing much larger patient populations.

With all this in mind, that makes the companies in this industry still higher risk than your traditional biotech and pharmaceutical stocks. A lot of these names are just getting started in their field, with many of them still being in pre-revenue stages. This is why we’ve opted for the strong name in the industry (CRSP) and the fund ARKG, which hold a basket of these companies. The genomics revolution is not dependent entirely on CRISPR. The broader ARKG thesis includes gene sequencing, molecular diagnostics, artificial intelligence assisted drug discovery, targeted cancer treatments, cell therapies, and the computing infrastructure needed to process massive amounts of biological data.

There will still be setbacks. Not every clinical trial will succeed, and many companies inside the genomics industry will fail. That is one reason an ETF such as ARKG can be attractive for investors seeking diversified exposure instead of attempting to predict which individual platform ultimately becomes the largest winner.

You’ve reached the end of our complimentary public watchlist. To unlock the full watchlist, real-time trade updates, entries, exits, and ongoing analysis, upgrade to Hyper Stocks Pro today.

Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice. Investing involves risk, including the possible loss of capital. Always conduct your own research or consult with a licensed financial advisor before making investment decisions.

Hyper Stocks and its contributors may hold positions in some of the securities or assets mentioned above. These positions are subject to change without notice. Any opinions expressed reflect current views at the time of writing and are not guarantees of future performance. Past performance does not guarantee future results.